What is the price difference between different versions of Jisandai/Bingtongsha?

As a targeted antiviral drug for the treatment of all genotypes of hepatitis C, Epclusa has been widely favored by doctors and patients around the world for its stable efficacy and convenient administration since its launch. Its applicable population includes treatment-naïve patients who have not received antiviral treatment, patients who have failed previous treatment, and special groups with compensated cirrhosis or HIV infection. It basically covers most clinical classifications of chronic hepatitis C. Epclusa, as one of the representative drugs of the pan-genotypic oral regimen, brings an unprecedented simplified process and high cure rate to the treatment of hepatitis C.

In terms of usage,Epclusa is a fixed-dose compound tablet that is taken orally once a day and can be used alone without the need for other drugs. It is especially suitable for patients who are intolerant to ribavirin or who want to shorten the treatment cycle. The treatment cycle is generally 12 weeks. Regardless of the genotype, there is no need to change the medication regimen based on the virus type, which greatly improves the convenience and compliance of treatment. It can also be used for some patients with liver cirrhosis, but whether to combine it with other drugs and whether to extend the course of treatment requires individualized assessment by doctors based on the patient's condition.

In China, Jisandai has been officially launched and included in the national medical insurance catalog. The specification is 400mg sofosbuvir + 100mg velpatasvir compound, each box is packed with 28 tablets. After being included in medical insurance, the price has been significantly reduced. Currently, the price in hospital pharmacies is generally around 3,000 yuan. This price is very attractive to patients who need a full course of treatment, and it also means that more patients can afford a complete treatment cycle and achieve hepatitis C cure.

Compared with this, the third-generation generic version of Jilin launched in foreign markets, especially India, Laos, and Bangladesh, has obvious price advantages because there is no additional patent cost. Take the third generation of India's Genisin as an example. The generic version of Sofosbuvir + Velpatasvir has the same specifications. The price per box is only about 800 yuan. It can even be purchased through overseas direct mail channels, making it an important choice for many economical patients.

Reference: https://www.epclusa.com/